ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO1005

The Role of the Inflammatory Chemokine CCL20 in Renal Injury in Multiple Myeloma

Session Information

  • Onco-Nephrology: Basic
    November 08, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Onco-Nephrology

  • 1500 Onco-Nephrology


  • Huang, Hong Dong, Capital Medical University, Beijing, Beijing, China
  • Liu, Sha, Capital Medical University, Beijing, China
  • Liu, Wenhu, Capital Medical University, Beijing, China

The pathogenesis of the occurrence and development of renal injury in myeloma is unclear. In this study to investigate the role of inflammatory chemokine CCL20 in multiple myeloma with kidney injury.


To detect the expression of CCL20 in renal tissue and bone marrow of multiple myeloma patients with kidney damage by Immunohistochemical technique. Using flow cytometry to analysis proliferation of myeloma cells with overexpression or lowexpression of CCL20. By qRT PCR and flow cytometry method to detect expression of myeloma cells infiltrating organize related receptor CXCR4 and ROBO4 with overexpression or knockdown CCL20. Establish myeloma cells transplantation model. Vitro imaging techniques were used to observe myeloma cells implanted into the bone marrow and kidney tissue. By flow cytometry, to analysis the graft rate(%) of myeloma cells and expression of CXCR4 and ROBO4 in bone marrow cell population and renal tissue on mice with overexpression or knockdown CCL20. Morbidity and survival situation were dynamically observed for mice with overexpression or knockdown CCL20.


The expression of CCL20 in myeloma and renal tissue was obviously higher than control group,and found that the myeloma cells with strong invasion ability had higher expression of CCL20 that suggested CCL20 were related with myeloma invasion ability. Showed that there was a difference in the ratio of immature cells in myeloma cells at different expression levels. The overexpression of CCL20 myeloma cell had significantly proliferated compared with the low expression of CCL20 myeloma cell. The CCL20 promoted the expression of CXCR4 and ROBO4 of myeloma cell. We had successfully established myeloma transplanted model. Animal experiments showed: After transplanting myeloma cells with knockdown CCL20 to immunodeficiency mice , myeloma cells badly survived and slightly damaged kidney. After transplanting overexpression of CCL20 myeloma cells to immunodeficiency mice, myeloma cell could survival well and damage kidney.The above thought that CCL20 in maintaining the survival of myeloma cells in bone marrow and renal tissue was necessary.


CCL20 plays an important role in the occurrence and development of renal injury in myeloma. Antagonistic CCL20 might be a new target for the prevention and treatment of renal injury in myeloma.


  • Government Support - Non-U.S.